New Dual-Action drug shows promise in early lung cancer trial
NCT ID NCT04995523
First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times
Summary
This study tests a new drug called rilvegostomig (AZD2936) in people with advanced or metastatic non-small cell lung cancer. The drug is designed to boost the immune system's ability to fight cancer by blocking two targets (TIGIT and PD-1). The trial will check for safety, side effects, and whether the drug can shrink tumors. About 212 participants will take part in this early-stage research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rilvegostomig (AZD2936), a bispecific antibody that targets two immune checkpoints (TIGIT and PD-1)
- What this could lead to
- If successful, this could provide a new treatment option for advanced lung cancer by helping the immune system attack cancer cells more effectively.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with a small number of participants, so safety and effectiveness are not yet proven. The drug may cause immune-related side effects or not work for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Chicago, Illinois, 60637, United States
-
Research Site
Rochester, Minnesota, 55905, United States
-
Research Site
Fairfax, Virginia, 22031, United States
-
Research Site
Melbourne, 3000, Australia
-
Research Site
Anderlecht, 1070, Belgium
-
Research Site
Leuven, 3000, Belgium
-
Research Site
Florianópolis, 88034-000, Brazil
-
Research Site
Natal, 59075-740, Brazil
-
Research Site
Porto Alegre, 90035903, Brazil
-
Research Site
Rio de Janeiro, 20231-050, Brazil
-
Research Site
São Paulo, 01246-000, Brazil
-
Research Site
Chengdu, 610041, China
-
Research Site
Chongqing, 400030, China
-
Research Site
Copenhagen, 2100, Denmark
-
Research Site
Dijon, 21079, France
-
Research Site
Toulouse, 31059, France
-
Research Site
Tbilisi, 0112, Georgia
-
Research Site
Kashiwa, 227-8577, Japan
-
Research Site
Niigata, 951-8566, Japan
-
Research Site
Sendai, 981-0914, Japan
-
Research Site
Tokyo, 104-0045, Japan
-
Research Site
Kuala Lumpur, 59100, Malaysia
-
Research Site
Kuching, 93586, Malaysia
-
Research Site
Chisinau, MD-2025, Moldova
-
Research Site
Groningen, 9713 GZ, Netherlands
-
Research Site
Leiden, 2333 ZA, Netherlands
-
Research Site
Utrecht, 3584 CX, Netherlands
-
Research Site
Seoul, 03082, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Barcelona, 08035, Spain
-
Research Site
Madrid, 28027, Spain
-
Research Site
Madrid, 28041, Spain
-
Research Site
Taichung, 40201, Taiwan
-
Research Site
Taichung, 40705, Taiwan
-
Research Site
Tainan, 70403, Taiwan
-
Research Site
Taipei, 110, Taiwan
-
Research Site
Bangkok, 10700, Thailand
-
Research Site
Chanthaburi, 22000, Thailand
-
Research Site
Muang, 50200, Thailand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted pill keep lung cancer from returning?
- Seeing Cancer's hidden markers: a new PET tracer could reveal who responds to targeted therapy
- Lab-Made immune protein takes on advanced cancers in first human test
- Experimental combo for lung cancer shows promise but study cut short
- New study tracks how well a targeted lung cancer drug works in everyday clinics
- New 4D scan could sharpen lung cancer radiation